209 related articles for article (PubMed ID: 36162918)
1. TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity.
Kaminski MF; Bendzick L; Hopps R; Kauffman M; Kodal B; Soignier Y; Hinderlie P; Walker JT; Lenvik TR; Geller MA; Miller JS; Felices M
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36162918
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
[TBL] [Abstract][Full Text] [Related]
3. Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers.
Cheng Y; Zheng X; Wang X; Chen Y; Wei H; Sun R; Tian Z; Sun H
Cancer Biol Med; 2020 Nov; 17(4):1026-1038. PubMed ID: 33299651
[TBL] [Abstract][Full Text] [Related]
4. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells.
Arvindam US; van Hauten PMM; Schirm D; Schaap N; Hobo W; Blazar BR; Vallera DA; Dolstra H; Felices M; Miller JS
Leukemia; 2021 Jun; 35(6):1586-1596. PubMed ID: 33097838
[TBL] [Abstract][Full Text] [Related]
5. Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager.
Felices M; Lenvik TR; Kodal B; Lenvik AJ; Hinderlie P; Bendzick LE; Schirm DK; Kaminski MF; McElmurry RT; Geller MA; Eckfeldt CE; Vallera DA; Miller JS
Cancer Immunol Res; 2020 Sep; 8(9):1139-1149. PubMed ID: 32661096
[TBL] [Abstract][Full Text] [Related]
6. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.
Vallera DA; Felices M; McElmurry R; McCullar V; Zhou X; Schmohl JU; Zhang B; Lenvik AJ; Panoskaltsis-Mortari A; Verneris MR; Tolar J; Cooley S; Weisdorf DJ; Blazar BR; Miller JS
Clin Cancer Res; 2016 Jul; 22(14):3440-50. PubMed ID: 26847056
[TBL] [Abstract][Full Text] [Related]
7. Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity.
Schmohl JU; Felices M; Oh F; Lenvik AJ; Lebeau AM; Panyam J; Miller JS; Vallera DA
Cancer Res Treat; 2017 Oct; 49(4):1140-1152. PubMed ID: 28231426
[TBL] [Abstract][Full Text] [Related]
8. Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker.
Schmohl JU; Felices M; Todhunter D; Taras E; Miller JS; Vallera DA
Oncotarget; 2016 Nov; 7(45):73830-73844. PubMed ID: 27650544
[TBL] [Abstract][Full Text] [Related]
9. Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker.
Schmohl JU; Felices M; Taras E; Miller JS; Vallera DA
Mol Ther; 2016 Aug; 24(7):1312-22. PubMed ID: 27157665
[TBL] [Abstract][Full Text] [Related]
10. A tri-specific killer engager against mesothelin targets NK cells towards lung cancer.
Kennedy PR; Vallera DA; Ettestad B; Hallstrom C; Kodal B; Todhunter DA; Bendzick L; Hinderlie P; Walker JT; Pulkrabek B; Pastan I; Kratzke RA; Fujioka N; Miller JS; Felices M
Front Immunol; 2023; 14():1060905. PubMed ID: 36911670
[TBL] [Abstract][Full Text] [Related]
11. Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL.
Felices M; Kodal B; Hinderlie P; Kaminski MF; Cooley S; Weisdorf DJ; Vallera DA; Miller JS; Bachanova V
Blood Adv; 2019 Mar; 3(6):897-907. PubMed ID: 30890546
[TBL] [Abstract][Full Text] [Related]
12. Multimeric immunotherapeutic complexes activating natural killer cells towards HIV-1 cure.
Schober R; Brandus B; Laeremans T; Iserentant G; Rolin C; Dessilly G; Zimmer J; Moutschen M; Aerts JL; Dervillez X; Seguin-Devaux C
J Transl Med; 2023 Nov; 21(1):791. PubMed ID: 37936122
[TBL] [Abstract][Full Text] [Related]
13. Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release.
Szot C; Saha S; Zhang XM; Zhu Z; Hilton MB; Morris K; Seaman S; Dunleavey JM; Hsu KS; Yu GJ; Morris H; Swing DA; Haines DC; Wang Y; Hwang J; Feng Y; Welsch D; DeCrescenzo G; Chaudhary A; Zudaire E; Dimitrov DS; St Croix B
J Clin Invest; 2018 Jul; 128(7):2927-2943. PubMed ID: 29863500
[TBL] [Abstract][Full Text] [Related]
14. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
[TBL] [Abstract][Full Text] [Related]
15. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors.
Raja Gabaglia C; Diaz de Durana Y; Graham FL; Gauldie J; Sercarz EE; Braciak TA
Cancer Res; 2007 Mar; 67(5):2290-7. PubMed ID: 17332360
[TBL] [Abstract][Full Text] [Related]
16. IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.
Felices M; Chu S; Kodal B; Bendzick L; Ryan C; Lenvik AJ; Boylan KLM; Wong HC; Skubitz APN; Miller JS; Geller MA
Gynecol Oncol; 2017 Jun; 145(3):453-461. PubMed ID: 28236454
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1.
Xu Y; Sun J; Sheard MA; Tran HC; Wan Z; Liu WY; Asgharzadeh S; Sposto R; Wu HW; Seeger RC
Cancer Immunol Immunother; 2013 Oct; 62(10):1637-48. PubMed ID: 23982484
[TBL] [Abstract][Full Text] [Related]
18. NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo.
Vallera DA; Ferrone S; Kodal B; Hinderlie P; Bendzick L; Ettestad B; Hallstrom C; Zorko NA; Rao A; Fujioka N; Ryan CJ; Geller MA; Miller JS; Felices M
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32961861
[TBL] [Abstract][Full Text] [Related]
19. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15.
Imamura M; Shook D; Kamiya T; Shimasaki N; Chai SM; Coustan-Smith E; Imai C; Campana D
Blood; 2014 Aug; 124(7):1081-8. PubMed ID: 25006133
[TBL] [Abstract][Full Text] [Related]
20. High and selective cytotoxicity of ex vivo expanded allogeneic human natural killer cells from peripheral blood against bladder cancer: implications for natural killer cell instillation after transurethral resection of bladder tumor.
Wang F; Zhang G; Xu T; Ma J; Wang J; Liu S; Tang Y; Jin S; Li J; Xing N
J Exp Clin Cancer Res; 2024 Jan; 43(1):24. PubMed ID: 38245792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]